natgillin/translations-raw huggingface dataset:
However, the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of in vitro solubility.
Međutim, koncentracija sulfatnih konjugata hidroksiaripiprazola u ljudskoj žuči kod najviše predložene doze od 30 mg na dan nije bila veća od 6 % koncentracije u žuči pronađene u majmuna u
Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.
Odmah obavijestite svog liječnika ako razmišljate o tome da si naudite.
If you stop receiving Abilify Maintena
Ako prestanete primati Abilify Maintena
Avoid use
Izbjegavati primjenu
When used concomitantly with strong CYP3A4 inhibitors the dose should be reduced to 200 mg (see section 4.5).
Kad se istovremeno primjenjuju jaki inhibitori CYP3A4, dozu treba smanjiti na 200 mg (vidjeti dio 4.5).
A number of symptoms of dystonia are then listed, including spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
Zatim je naveden određeni broj simptoma distonije, uključujući grč vratnih mišića, koji ponekad napreduje do stezanja grla, otežanog gutanja, otežanog disanja i/ili protruzije jezika.
• increased blood fats such as high cholesterol, high triglycerides and also low level of cholesterol and low level of triglycerides
• visok šećer u krvi • povišene masnoće u krvi, kao što je kolesterol, visoki trigliceridi i također niska razina kolesterola i niska razina triglicerida
The estimated relapse rate by end of Week 26 was 7.12 % for Abilify Maintena, and 7.76 % for oral aripiprazole tablets 10-30 mg, a difference of -0.64 %.
Procijenjena stopa relapsa do kraja 26. tjedna iznosila je 7,12 % uz Abilify Maintena i 7,76 % uz tablete oralnog aripiprazola od 10-30 mg, što čini razliku od −0,64 %.
• abnormal hair loss
• nenormalan gubitak kose
Overall, 1.3 % of oral aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials.
U tim je ispitivanjima ukupno 1,3 % bolesnika liječenih oralnim aripiprazolom prijavilo cerebrovaskularne nuspojave u usporedbi s 0,6 % bolesnika koji su primali placebo.
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2).
U slabih CYP2D6 metabolizatora, istovremena primjena jakih inhibitora CYP3A4 može dovesti do viših koncentracija aripiprazola u plazmi u usporedbi s jakim CYP2D6 metabolizatorima (vidjeti dio 4.2).
It has been proposed that aripiprazole's efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors.
Predloženo tumačenje djelotvornosti aripiprazola u shizofreniji jest da je ono posredovano kombinacijom djelomičnog agonizma s dopaminskim D2 i serotoninskim 5-HT1A receptorima i antagonizma sa serotoninskim 5-HT2A receptorima.
Care must be taken to avoid inadvertent injection into the blood vessel.
Neophodan je oprez da bi se izbjegla nehotična injekcija u krvnu žilu.
Expel air until suspension fills needle base*
Istisnite zrak sve dok suspenzija ne ispuni bazu igle*
• enlargement of breast in men, breast tenderness, vaginal dryness
• povećanje dojki u muškaraca, osjetljivost dojki, suhoća rodnice
Needle cap d) Then pull needle-cap straight up.
Poklopac igle d) Zatim povucite poklopac igle ravno prema gore.
After multiple dose administration of Abilify Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1-32.5 % of aripiprazole AUC in plasma.
Abilify Maintena, dehidroaripiprazol, djelatni metabolit, čini oko 29,1 % do 32,5 % AUC-a aripiprazola u plazmi.
This trial consisted of a screening phase and 4 treatment phases: Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and Double-blind Placebo-controlled.
Ovo se ispitivanje sastojalo od faze probira i 4 terapijske faze: faze konverzije, oralne stabilizacije, stabilizacije na Abilify Maintena i dvostruko slijepe, placebom kontrolirane faze.
When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.
Kad se slabi inhibitori CYP3A4 (npr., diltiazem) ili CYP2D6 (npr., escitalopram) primjenjuju istodobno s aripiprazolom, mogu se očekivati umjerena povećanja koncentracije aripiprazola u plazmi.
Abilify Maintena comes in a pre-filled syringe containing a white to off-white powder in the front chamber and a clear solvent in the rear chamber.
Abilify Maintena dolazi u napunjenoj štrcaljki koja sadrži bijeli do gotovo bijeli prašak u prednjoj komori i bistro otapalo u stražnjoj komori.
The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels.
Istodobnu primjenu induktora CYP3A4 s lijekom Abilify Maintena treba izbjegavati zato što su koncentracije aripiprazola u krvi snižene i mogu biti ispod razine učinkovitosti.
Your doctor will give it to you as a single injection into the gluteal or deltoid muscle (buttock or shoulder) every month.
Liječnik će Vam svakog mjeseca dati jednu injekciju lijeka u glutealni mišić (mišić stražnjice) ili deltoidni mišić (mišić ramena).
The incidences of the ADRs associated with aripiprazole therapy are tabulated below.
Incidencija nuspojava povezanih s terapijom aripiprazolom prikazana je u tablici niže.
By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping.
Do 7. dana, medijan koncentracije aripiprazola nastavlja opadati do koncentracija nakon intramuskularne depo-doze bez naglog oslobađanja cijele doze.
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 5.2).
Prescribers need to be aware of the long-acting properties of Abilify Maintena.
Liječnici koji propisuju lijek trebaju biti svjesni dugotrajnih svojstava lijeka Abilify Maintena.
• low sodium level in the blood
• niska razina natrija u krvi
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively.
U kliničkim ispitivanjima oralnog aripiprazola u zdravih ispitanika, jaki inhibitor CYP3A4 (ketokonazol) povećao je AUC aripiprazola za 63 %, a Cmax za 37 %.
Elaiapharm2881 Route des Crêtes Z.I Les Bouillides Sophia Antipolis 06550 Valbonne
Les Bouillides Sophia Antipolis 06550 Valbonne
Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
Simptomi distonije uključuju grč mišića vrata, koji ponekad napreduje do stezanja grla, otežanog gutanja, otežanog disanja i/ili protruzije jezika.
Sudden unexplained death Cardiac arrest Torsades de pointes Ventricular arrhythmias QT prolongation
srčani arest, torsades de pointes ventrikularne aritmije, produljenje QT intervala
Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone.
Nakon istodobne primjene karbamazepina, jakog induktora CYP3A4, i peroralnog aripiprazola bolesnicima sa shizofrenijom ili shizoafektivnim poremećajem, geometrijska srednja vrijednost Cmax aripiprazola bila je 68 %, a AUC-a 73 % niža u usporedbi s onima kad se oralni aripiprazol (30 mg)
When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain was more frequent in the deltoid muscle.
U usporedbi s ispitivanjima u kojima se Abilify Maintena injicirao u glutealni mišić, ponovna pojava bola na mjestu injekcije bila je češća kod deltoidnog mišića.
* 200 mg and 160 mg can be achieved via adjustment of the injection volume only by using Abilify Maintena powder and solvent for prolonged-release suspension for injection.
* Doze od 200 mg i 160 mg se mogu postići prilagođavanjem volumena injekcije samo ako se koristi Abilify Maintena prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Add 1.5 ml solvent to reconstitute the powder.
Dodajte 1,5 ml otapala da biste rekonstituirali prašak.
Talk to your doctor about the best way to feed your baby if you are receiving Abilify Maintena.
Razgovarajte sa svojim liječnikom o najboljem načinu na koji da hranite svoje dijete ako primate
Less than doseproportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters are observed after monthly Abilify Maintena injections of 300 mg to 400 mg.
Povećanje koncentracije i AUC-a aripiprazola i dehidroaripiprazola manje od onog ovisnog o dozi opaženo je nakon mjesečnih injekcija lijeka Abilify Maintena od 300 mg do 400 mg.
Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Abilify Maintena je indiciran za terapiju održavanja u liječenju shizofrenije u odraslih bolesnika stabiliziranih na oralnom aripiprazolu.
Weight gain is commonly seen in schizophrenic patients due to use of antipsychotics known to cause weight gain, co-morbidities, poorly managed life-style and might lead to severe complications.
Povećanje tjelesne težine često se viđa u bolesnika sa shizofrenijom zbog primjene antipsihotika za koje se zna da uzrokuju povećanje tjelesne težine, komorbiditeta, nezdravog načina života i može dovesti do teških komplikacija.
Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section 4.5).
Istovremenu primjenu induktora CYP3A4 s lijekom Abilify Maintena treba izbjegavati dulje od 14 dana zato što su koncentracije aripiprazola u krvi snižene i mogu biti ispod razine djelotvornosti (vidjeti dio 4.5).
Abilify Maintena powder and solvent for prolonged-release suspension for injection The suspension should be injected immediately after reconstitution but can be stored below 25 °C for up to 4 hours in the vial.
Abilify Maintena prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Suspenziju treba ubrizgati odmah nakon rekonstitucije, iako se može čuvati u bočici na temperaturi ispod 25 °C najviše 4 sata.
The powder and solvent vials are for single-use only.
Bočice praška i otapala samo su za jednokratnu uporabu.
Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).
S obzirom na primarne učinke aripiprazola na središnji živčani sustav (SŽS), potreban je oprez kad se aripiprazol primjenjuje u kombinaciji s alkoholom ili drugim lijekovima koji djeluju na SŽS i čije se nuspojave, kao što je sedacija, preklapaju (vidjeti dio 4.8).
Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10-30 mg.
Stoga Abilify Maintena nije inferioran aripiprazolu u obliku oralnih tableta od 10-30 mg.
Dizziness and vision problems may occur during treatment with this medicine (see section 4).
Tijekom liječenja ovim lijekom mogu se javiti omaglica i problemi s vidom (pogledajte dio 4).
• grinding of teeth or clenching of the jaw
• škrgutanje zubima ili čvrsto stiskanje čeljusti
One vial of powder
Jednu bočicu praška
• acne, skin condition of the face where the nose and cheeks are unusually red, eczema, skin hardening
• nenormalan gubitak kose • akne, stanje kod kojeg je koža nosa i obraza neobično crvena, ekcem, otvrdnuće kože
In clinical trials, rare cases of NMS were reported during treatment with aripiprazole.
U kliničkim su ispitivanjima zabilježeni rijetki slučajevi NMS-a tijekom liječenja aripiprazolom.
Weight gain has been reported post-marketing among patients prescribed oral aripiprazole.
Povećanje tjelesne težine zabilježeno je nakon stavljanja lijeka u promet među bolesnicima kojima je bio propisan oralni aripiprazol.
b) Using the syringe with pre-attached needle, withdraw the pre-determined solvent volume from the vial of the solvent into the syringe.
b) Pomoću štrcaljke s već spojenom iglom izvucite prethodno utvrđeni volumen otapala iz bočice otapala u štrcaljku.
• thirstiness more than usual, need to urinate more than usual, feel very hungry, feel weak or tired, feel sick, feel confused or your breath smells fruity, since this may be a sign of diabetes.
• Jaču žeđ nego obično, potrebu da mokrite više nego obično, jaku glad, osjećaj slabosti ili umora, mučninu, smetenost ili voćni miris u dahu, jer to može biti znak šećerne bolesti.
Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).
Aripiprazol treba primjenjivati s oprezom u bolesnika s produljenjem QT intervala u obiteljskoj anamnezi (vidjeti dio 4.8).
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy.
Nakon prekida primjene inhibitora CYP2D6 ili CYP3A4, dozu aripiprazola treba povisiti na dozu prije početka istodobne terapije.
Maintenance treatment of schizophrenia in adults The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double-blind, long-term trials.
Djelotvornost lijeka Abilify Maintena u terapiji održavanja u liječenju bolesnika sa shizofrenijom bila je ustanovljena u dva randomizirana dvostruko slijepa, dugotrajna ispitivanja.
Multipack: Three single packages, each containing:
Višestruko pakiranje: tri pojedinačna pakiranja, od kojih svako sadrži: Jednu bočicu praška
The powder and solvent vials and the pre-filled syringe are for single-use only.
Bočice s praškom i otapalom i napunjena štrcaljka su samo za jednokratnu primjenu.
And then, rotate plunger rod until the rod stops rotating to release diluent.
Potom zakrećite klip sve dok se ne zaustavi kako bi se oslobodilo otapalo.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).
U kliničkim ispitivanjima u odobrenim indikacijama i nakon stavljanja lijeka u promet, uz aripiprazol je opaženo i povišenje i sniženje prolaktina u serumu u usporedbi s početnim vrijednostima (dio 5.1).
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects.
Nakon oralne primjene aripiprazola, nema razlika u farmakokinetici aripiprazola između zdravih muškaraca i žena.
Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:
Lijekovi koji povisuju razinu serotonina obično se primjenjuju u stanjima koja uključuju depresiju, generalizirani anksiozni poremećaj, opsesivno-kompulzivni poremećaj i socijalnu fobiju, kao i migrenu i bol:
Abilify Maintena contains sodium
Abilify Maintena sadrži natrij
Six-hundred and sixty two patients eligible for the 38-week Double-blind, Active-controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation dose of oral aripiprazole 10-30 mg, or 3) aripiprazole LongActing Injectable 50 mg/25 mg.
Šest stotina i šezdeset dva bolesnika podobna za 38-tjednu, dvostruko slijepu fazu s aktivnom kontrolom bila su randomizirana u omjeru 2:2:1 u jednu od 3 terapijske skupine za dvostruko slijepo liječenje: 1) lijekom Abilify Maintena 2) stabilizacijskom dozom oralnog aripiprazola od 10-30 mg ili 3) dugodjelujućim aripiprazolom u injekcijama od 50 mg/25 mg.
How Abilify Maintena is given
Kako se daje Abilify Maintena
Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)
anafilaktička reakcija, angioedem uključujući otečen jezik, edem jezika, edem lica, svrbež i urtikariju)
The front chamber between front stopper and middle stopper contains the powder and the rear chamber between middle stopper and end stopper the solvent.
Prednja komora između prednjeg čepa i srednjeg čepa sadrži prašak, dok stražnja komora između srednjeg čepa i stražnjeg čepa sadrži otapalo.
Excess amount of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube that goes from mouth to stomach through which food passes),
u jednjak (ezofagus ili cjevasti organ koji se proteže od usta do želuca i kroz koji prolazi hrana),
Aripiprazole exhibits high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and has moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic, and histamine H1 receptors.
Aripiprazol pokazuje visok afinitet vezanja in vitro za dopaminske D2 i D3 i serotoninske 5-HT1A i 5-HT2A receptore i ima umjereni afinitet prema dopaminskim D4, serotoninskim
• experience a combination of fever, sweating, faster breathing, muscle stiffness and drowsiness or sleepiness (may be signs of neuroleptic malignant syndrome)
• kombinacije vrućice, znojenja, ubrzanog disanja, mišićne ukočenosti i omamljenosti ili pospanosti (mogu biti znakovi malignog neuroleptičnog sindroma)
If the injection is not performed immediately after reconstitution shake it vigorously for at least 60 seconds to re-suspend prior to injection.
Ako se injekcija ne primijeni odmah nakon rekonstitucije, prije injekcije žustro je tresite najmanje 60 sekundi zbog ponovne suspenzije.
The incidences of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) was 1.9 % compared to 7.1 % for placebo patients.
Incidencija bolesnika na lijeku Abilify Maintena s razinom prolaktina > 1 puta iznad gornje granice normale (GGN) bila je 1,9 % u usporedbi sa 7,1 % bolesnika koji su primali placebo.
• a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness since this may be a sign of a condition called neuroleptic malignant syndrome (NMS).
• Kombinacija vrućice, ubrzanog disanja, znojenja, ukočenosti mišića i omamljenosti ili pospanosti, jer to može biti znak stanja koje se zove maligni neuroleptički sindrom.
If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8).
Ako se u bolesnika koji prima aripiprazol pojave znakovi i simptomi tardivne diskinezije, potrebno je razmotriti smanjenje doze ili prekid primjene (vidjeti dio 4.8).
The safety profile was consistent with that known to Abilify Maintena.
Profil sigurnosti bio je sukladan poznatom profilu lijeka Abilify Maintena.
Discard vial, adapter, syringe, needles, unused suspension and water for injections appropriately.
Bočicu, nastavak, štrcaljku, igle, nepotrošenu suspenziju i vodu za injekcije zbrinite na odgovarajući način.
The incidence of weight loss of ≥ 7 % from baseline to last visit was 6.4 % for Abilify Maintena and 6.7 % for placebo.
Incidencija gubitka na tjelesnoj težini za ≥ 7 % na posljednjem posjetu u odnosu na početnu bila je 6,4 % uz Abilify Maintena i 6,7 % uz placebo.
The AUC and Cmax of dehydroaripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.
AUC dehidroaripiprazola, djelatnog metabolita, smanjio se za 32 %, a Cmax za 47 %.
In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole.
U kliničkim ispitivanjima u trajanju od godinu dana ili kraće, diskinezija povezana s liječenjem je manje često prijavljena nuspojava tijekom liječenja aripiprazolom.
Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reduction should, therefore, be applied (see section 4.2).
Drugi jaki inhibitori CYP2D6, kao što su fluoksetin i paroksetin, mogu očekivano imati slične učinke pa je stoga potrebno na sličan način sniziti dozu (vidjeti dio 4.2).
Step 2: Reconstitution of the powder a) Push plunger rod slightly to engage threads.
Korak 2: Rekonstitucija praška a) Malo potisnite klip tako da se zahvati navoj.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)
(uključujući plućnu emboliju i duboku vensku trombozu)
Shake the vial vigorously for at least 30 seconds until the suspension appears uniform.
Žustro tresite bočicu najmanje 30 sekundi sve dok suspenzija ne dobije jednoličan izgled.
• past experience with excessive gambling
• prethodnog iskustva pretjeranog kockanja • velike tegobe s jetrom.
The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively.
AUC dehidroaripiprazola povećao se za 77 %, a Cmax za 43 %.
The incidence of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) at any assessment was 5.4 % compared with 3.5 % of the patients on oral aripiprazole tablets 10-30 mg.
Incidencija bolesnika koji su primali Abilify Maintena i imali razine prolaktina > 1 puta iznad gornje granice normale (GGN) na bilo kojoj procjeni bila je 5,4 % u usporedbi s 3,5 % u bolesnika koji su uzimali tablete oralnog aripiprazola od 10-30 mg.
• increased levels of insulin, a hormone regulating blood sugar levels
• povišene razine inzulina, hormona koji regulira razine šećera u krvi • smanjen ili povećan apetit
Do not use this medicine after the expiry date which is stated on the carton and the vial.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici.
Abilify Maintena comes as a white to off-white powder in a clear glass vial.
Abilify Maintena je bijeli do gotovo bijeli prašak u prozirnoj staklenoj bočici.
• other anti-depressants (such as venlafaxine and tryptophan) used in major depression
• drugi antidepresivi (kao što su venlafaksin i triptofan) koji se primjenjuju kod teške depresije
Patients eligible for the Double-blind, Placebo-controlled Phase were randomly assigned in a 2:1 ratio to double-blind treatment with Abilify Maintena or placebo, respectively.
Bolesnici pogodni za dvostruko slijepu, placebom kontroliranu fazu bili su randomizirani u omjeru 2:1 u skupinu koja je na dvostruko slijepi način primala liječenje lijekom Abilify Maintena ili u skupinu koja je primala placebo.
Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).
Na temelju populacijske farmakokinetičke procjene lijeka Abilify Maintena, ukupni klirens aripiprazola iz tijela bio je 3,71 l/h u jakih CYP2D6 metabolizatora i približno 1,88 l/h (približno 50 %
In an open label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site related reactions were slightly more frequent in the deltoid muscle.
U otvorenom ispitivanju u kojem se uspoređivala bioraspoloživost lijeka Abilify Maintena primijenjenog u deltoidni ili glutealni mišić, reakcije povezane s mjestom injekcije bile su nešto češće kod deltoidnog mišića.
i) Do not store the reconstituted suspension in the syringe.
i) Rekonstituiranu suspenziju nemojte čuvati u štrcaljki.
Do not use this medicine after the expiry date which is stated on the carton and the pre-filled syringe.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i napunjenoj štrcaljki.